Biologics and gene therapies are the future of medicine. Anew Medical, Inc. (“Anew Medical” or “ANEW” was formed in 2021 to develop cutting-edge biologic medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. As we age and get older, these diseases become the major cause of death or disablement. There are two wholly-owned subsidiaries under management by the Anew Medical team – Anew Biologics, Inc. uses state-of-the-art biologic therapies to treat cancer – using recombinant proteins made outside the body, and Anew Gene Therapy, Inc. which uses a gene therapy approach to introduce a gene to make therapeutic proteins inside the body – to either block factors causing disease or to replace human genes that have either shut down native protein production or have mutated to produce aberrant proteins that do not function at all.
This website may contain forward-looking statements that involve risks, uncertainties, and assumptions. All statements other than statements of historical fact could be deemed forward-looking statements, including any projections of revenues, gross margins, earnings, or other financial items; statements regarding strategies or plans for future operations; statements concerning our products; statements relating to the expected performance or benefits of our offerings; statements about current or future economic conditions; and any other statements of expectation or belief. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements, and therefore you should not rely on any forward-looking statements that we may make.
The risks and uncertainties referred to above include, but are not limited to, our history of losses and expectations as to future losses, limited operating history, competition, management of growth, development of the market for our therapeutics, market acceptance of our products, compliance with global laws and regulations, risks associated with maintaining a global business and global economic conditions, fluctuations in our operating results, and risks associated with regulatory approvals and compliance.
Anew Medical assumes no obligation for, and does not intend to update, any forward-looking statements.